-transparent.png){kind=logo}
A therapeutic trial is described which concerns 6 patients with AIDS and 6 patients with ARC who were submitted to a 6 month course of Ribavirin. Ribavirin was administered orally as the following doses: 3.000 mg daily the first week, 2.000 mg daily the second 2 weeks, and 1.000 mg daily up to completion of the 6 months period. No major side-effects were recorded; only a transient anemia was observed in almost all patients at the higher dose; none of them, however, required to be transfused. No improvement was shown by any of the 6 AIDS patients, neither clinically nor according to laboratory test, whereas all 6 patients with ARC experienced a sense of well-being, a clearing of their symptoms and an average weight gain of about 2.5 kg. No significant changes, though, were recorded as for their immune parameters. A remarkable drop of aminotransfereas was also observed in 4 of the patients, who were affected with chronic hepatitis as well. We conclude that additional, if any, Ribavirin trials should be carried out only in ARC patients.
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
August 1986,
Lancet (London, England),
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
January 1993,
The Journal of infectious diseases,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
January 1990,
Reviews of infectious diseases,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
September 1992,
The Journal of infectious diseases,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
January 1991,
Current topics in pathology. Ergebnisse der Pathologie,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
July 1991,
Lancet (London, England),
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
December 1988,
The Journal of infectious diseases,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
October 1993,
Clinical and diagnostic virology,
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
December 1988,
Lancet (London, England),
P Crocchiolo, and
R Pristera, and
A Lazzarin, and
M Chemotti, and
M Froldi, and
E Palazzini, and
P Verani, and
A Orecchia, and
M Moroni
June 1990,
Journal of clinical psychopharmacology,
